FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Aristidis Polyzos

Research Profile

Procedures

Chemicals & Drugs

Concepts & Ideas

Disorders

Co-author Network

Publications

TOP 3
Ioannis Boukovinas; Constantine A Constantinides; Nikolaos Androulakis; Athanasios Karampeazis; Nikolaos Kentepozidis; Athanasios Kostakopoulos; Athanasios Kotsakis; Vassilis Markos; Dimitris Mavroudis; Pavlos Papakotoulas; Aristidis Polyzos; George Samonis; Nikolaos Vardakis; Nikolaos Ziras; Vassilis Georgoulias
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
John Souglakos; Lambros Vamvakas; S Xynogalos; Nikolaos Ziras; Ioannis Boukovinas; Ch Christophyllakis; Vassilis Georgoulias; Stylianos Kakolyris; Nikolaos Kentepozidis; Ch Kouroussis; P Makrantonakis; Aristidis Polyzos
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Aristidis Polyzos; Emmanouel Saloustros; Nikolaos Vardakis; Vassiliki Bozionelou; Vassilis Georgoulias; Stylianos Giassas; Kostas Kalbakis; Antonia Kalykaki; Nikolaos Kentepozidis; Emmanouel Kontopodis; Dimitris Mavroudis
Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Aristidis Polyzos (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Ioannis Boukovinas; Constantine A Constantinides; Nikolaos Androulakis; Athanasios Karampeazis; Nikolaos Kentepozidis; Athanasios Kostakopoulos; Athanasios Kotsakis; Vassilis Markos; Dimitris Mavroudis; Pavlos Papakotoulas; Aristidis Polyzos; George Samonis; Nikolaos Vardakis; Nikolaos Ziras; Vassilis Georgoulias
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Cancer chemotherapy and pharmacology 2012;69(2):351-6.
2012: John Souglakos; Lambros Vamvakas; S Xynogalos; Nikolaos Ziras; Ioannis Boukovinas; Ch Christophyllakis; Vassilis Georgoulias; Stylianos Kakolyris; Nikolaos Kentepozidis; Ch Kouroussis; P Makrantonakis; Aristidis Polyzos
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
British journal of cancer 2012;106(3):453-9.
2011: Aristidis Polyzos; Emmanouel Saloustros; Nikolaos Vardakis; Vassiliki Bozionelou; Vassilis Georgoulias; Stylianos Giassas; Kostas Kalbakis; Antonia Kalykaki; Nikolaos Kentepozidis; Emmanouel Kontopodis; Dimitris Mavroudis
Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.
Cancer chemotherapy and pharmacology 2011;68(1):217-23.
2011: Ourania Katopodis; Aristidis Polyzos; Nikolaos Kentepozidis; Stylianos Giassas; Maria Rovithi; Vasiliki Bozionelou; Kostas Kalbakis; Lambros Vamvakas; Dimitris Mavroudis; Vassilis Georgoulias
Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Cancer chemotherapy and pharmacology 2011;67(2):361-8.
2010: Nikos Xenidis; Athanasios Kotsakis; Antonia Kalykaki; Ch Christophyllakis; Stylianos Giassas; Nikolaos Kentepozidis; Aristidis Polyzos; L Chelis; Nikolaos Vardakis; Lambros Vamvakas; Vassilis Georgoulias; Stylianos Kakolyris
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Lung cancer (Amsterdam, Netherlands) 2010;68(3):450-4.
2010: Helen Gogas; Urania Dafni; Henry Koon; Maria Spyropoulou-Vlachou; Yannis Metaxas; Elizabeth Buchbinder; Eirini Pectasides; Dimosthenis A Tsoutsos; Aristidis Polyzos; Alexander J Stratigos; Christos Markopoulos; Petros Panagiotou; George Fountzilas; Ourania Castana; Pantelis Skarlos; Michael B Atkins; John M Kirkwood
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.
Journal of translational medicine 2010;8():108.
2010: Niki Karachaliou; Aristidis Polyzos; Nikolaos Kentepozidis; Stylianos Kakolyris; Nikolaos Ziras; Nikolaos Vardakis; Antonia Kalykaki; Georgia Milaki; Vassilis Georgoulias; Nikolaos Androulakis
A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract.
Oncology 2010;78(5-6):356-60.
2010: Sofia Agelaki; Dora Hatzidaki; Athanasios Kotsakis; Pavlos Papakotoulas; Aristidis Polyzos; Nikolaos Ziras; Ioannis Gioulbasanis; Athanasios Karampeazis; Athina Agelidou; Xanthi Tsiafaki; Vassilis Chandrinos; Maria Lerikou; Vassilis Georgoulias
Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group.
Oncology 2010;78(3-4):229-36.
2010: Dimitris Mavroudis; Pavlos Papakotoulas; Alexandros Ardavanis; Konstantinos Syrigos; Stylianos Kakolyris; Nikolaos Ziras; Charalambos Kouroussis; N Malamos; Aristidis Polyzos; C Christophyllakis; Nikolaos Kentepozidis; Vassilis Georgoulias
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(1):48-54.
2009: Nicolas Tsavaris; Christos Kosmas; Nikitas Papadoniou; P Kopteridis; K Tsigritis; A Dokou; J Sarantonis; H Skopelitis; M Tzivras; K Gennatas; Aristidis Polyzos; George Papastratis; Gabriel Karatzas; P Kopterides; A Papalambros
CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Journal of chemotherapy (Florence, Italy) 2009;21(6):673-80.
2009: Eleni Karapanagiotou; Aristidis Polyzos; Kalliopi D Dilana; Ioannis Gratsias; Paraskevi Boura; Ioannis Gkiozos; Konstantinos N Syrigos
Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients.
Lung cancer (Amsterdam, Netherlands) 2009;66(3):393-8.
2009: Aristidis Polyzos; Helen Gogas; Christos Markopoulos; Nicolas Tsavaris; Othon Papadopoulos; Kostas Polyzos; Aris Giannopoulos
Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes.
Anticancer research 2009;29(7):2851-6.
2009: Aristidis Polyzos; Nicolas Tsavaris; Helen Gogas; Antonios Lagadas; Kostas Polyzos; Kostas Giannakopoulos; Evangelos Felekouras; Christos Tsigris; Theodoros Karatzas; Othon Papadopoulos; Aris Giannopoulos
Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel.
Anticancer research 2009;29(7):2681-6.
2009: Evangelos Terpos; Maria Kiagia; Eleni Karapanagiotou; Adrianni Charpidou; Kaliopi D Dilana; Efthimia Nasothimiou; Kevin J Harrington; Aristidis Polyzos; Konstantinos N Syrigos
The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications.
Anticancer research 2009;29(5):1651-7.
2009: ZACHAROULA PANTELEAKOU; PANAGIOTIS E. LEMBESSIS; Antigone Sourla; Nikolaos Pissimissis; Aristidis Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.
Molecular medicine (Cambridge, Mass.) 2009;15(3-4):101-14.
2009: Dimitrios Pectasides; Urania Dafni; Dimitrios Bafaloukos; Dimosthenis Skarlos; Aristidis Polyzos; Dimosthenis Tsoutsos; Haralambos Kalofonos; George Fountzilas; Petros Panagiotou; George Kokkalis; Othon Papadopoulos; Ourania Castana; Stefanos Papadopoulos; Elias Stavrinidis; Georgia Vourli; John Ioannovich; Helen Gogas
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(6):939-44.
2009: Nicolas Tsavaris; Nicolaos Kavantzas; KONSTANTINOS TSIGRITIS; Ioannis D Xynos; Nikitas Papadoniou; Andreas Lazaris; Christos Kosmas; George Agrogiannis; Anna Dokou; Evangelos Felekouras; Efstathios Antoniou; Aristidis Polyzos; John Sarantonis; Heraklis Tsipras; Gabriel Karatzas; Alexandros Papalambros; Efstratios S Patsouris
Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
BMC cancer 2009;9():264.
2008: Aristidis Polyzos
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
The Journal of steroid biochemistry and molecular biology 2008;108(3-5):261-6.
2008: Stylianos Kakolyris; John Souglakos; Aristidis Polyzos; Alexandros Ardavanis; Nikolaos Ziras; Athanasios Athanasiadis; I Varthalitis; Kyriakos Amarantidis; S Tsousis; Lambros Vamvakas; Nikolaos Vardakis; Vassilis Georgoulias
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Oncology 2008;74(1-2):31-6.
2008: Vassilis Georgoulias; Nikolaos Androulakis; Athanasios Kotsakis; Dora Hatzidaki; Konstantinos Syrigos; Aristidis Polyzos; Athina Agelidou; Ioannis Varthalitis; Nikolaos Ziras; Maria Agelidou; Vassilis Chandrinos; Ioannis Boukovinas; A Geroyianni; Lambros Vamvakas; Dimitris Mavroudis
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.
Lung cancer (Amsterdam, Netherlands) 2008;59(1):57-63.
2007: Christos Kosmas; Nicolas Tsavaris; Nikolaos Malamos; George Tsakonas; Argyris Gassiamis; Aristidis Polyzos; Nicolas Mylonakis; Athanasios Karabelis
Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.
Investigational new drugs 2007;25(5):463-70.
2007: Christos Kosmas; Nicolas Tsavaris; Nicolas Mylonakis; George Tsakonas; Argyris Gassiamis; Helias Skopelitis; Aristidis Polyzos; Nikolaos Malamos; Athanasios Karabelis
Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
Journal of chemotherapy (Florence, Italy) 2007;19(3):322-31.
2007: Aristidis Polyzos; Christos Kosmas; Nicolas Tsavaris; Helen Toufexi; Antonios Lagadas; Helen Gogas; Kostas Giannakopoulos; Gregory Kouraklis; John Griniatsos; Evangelos Felekouras; Christos Tsigris; Nikolaos Nikiteas; Othon Papadopoulos; Aris Giannopoulos
Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Anticancer research 2007;27(3B):1645-51.
2007: I Gkioulbasanis; John Souglakos; Nikolaos Vardakis; Athanasios Kotsakis; Zacharenia Saridaki; Nikolaos Kentepozidis; Aristidis Polyzos; Stylianos Giassas; Michail Ignatiadis; Vassiliki Bozionelou; Charalambos Christophylakis; Vassilis Georgoulias
Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2007;12(2):197-202.
2007: Eleni Petridou; Nicholas Mitsiades; Spyros Gialamas; Miltiadis Angelopoulos; Alkistis Skalkidou; Nick Dessypris; Alex Hsi; Nikolaos Lazaris; Aristidis Polyzos; Constantinos Syrigos; Aoife M Brennan; Sofia Tseleni-Balafouta; Christos S Mantzoros
Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies.
Oncology 2007;73(3-4):261-9.
2007: Nicolas Tsavaris; Christos Kosmas; Helias Skopelitis; Nikitas Papadoniou; Aristidis Polyzos; George C Zografos; Efstathios Adoniou; John Gryniatsos; Evangelos Felekouras; Michalis Zacharakis; Fragiska Sigala; Christos Bacoyiannis; George Papastratis; Efstathios Papalambros
Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
Chemotherapy 2007;53(4):282-91.
2006: Helen Gogas; Aristidis Polyzos; I Stavrinidis; Konstantina Frangia; Dimosthenis A Tsoutsos; Petros Panagiotou; Christos Markopoulos; Othon Papadopoulos; Dimitrios Pectasides; Marina Mantzourani; M Middleton; George Vaiopoulos; George Fountzilas
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(12):1835-41.
2006: Ioannis Boukovinas; Nikolaos Androulakis; Lambros Vamvakas; Pavlos Papakotoulas; Nikolaos Ziras; Aristidis Polyzos; Antonia Kalykaki; Athanasios Kotsakis; Nikos Xenidis; I Gioulmbasanis; Dimitris Mavroudis; Vassilis Georgoulias
Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(11):1687-92.
2006: George P Stathopoulos; Konstantinos Syrigos; Gerasimos Aravantinos; Aristidis Polyzos; Pavlos Papakotoulas; G Fountzilas; Anna Potamianou; Nikolaos Ziras; John Boukovinas; John Varthalitis; Nikolaos Androulakis; Athanasios Kotsakis; George Samonis; Vassilis Georgoulias
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
British journal of cancer 2006;95(5):587-92.
2006: Aristidis Polyzos; Nicolas Tsavaris; Christos Kosmas; Kostas Polyzos; Aris Giannopoulos; Evangelos Felekouras; Nikolaos Nikiteas; Gregory Kouraklis; John Griniatsos; Michael C Safioleas; Michael Stamatakos; Emmanouil Pikoulis; Antonios Papachristodoulou; Helen Gogas
Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin.
Anticancer research 2006;26(5B):3749-53.
2006: P Makrantonakis; Panagiotis Ziotopoulos; Athina Agelidou; Aristidis Polyzos; A Ziras; Vassilis Chandrinos; Andreas Vossos; Antonia Kalykaki; Nikolaos Androulakis; A Geroyianni; Vassilis Georgoulias
Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study.
Lung cancer (Amsterdam, Netherlands) 2006;53(1):85-90.
2006: John Souglakos; Nikolaos Androulakis; Konstantinos Syrigos; Aristidis Polyzos; Nikolaos Ziras; Athanasios Athanasiadis; Stylianos Kakolyris; S Tsousis; Ch Kouroussis; Lambros Vamvakas; Antonia Kalykaki; George Samonis; Dimitris Mavroudis; Vassilis Georgoulias
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
British journal of cancer 2006;94(6):798-805.
2006: Helen Gogas; John Ioannovich; Urania Dafni; Catherine Stavropoulou-Giokas; Konstantina Frangia; Dimosthenis A Tsoutsos; Petros Panagiotou; Aristidis Polyzos; Othon Papadopoulos; Alexander J Stratigos; Christos Markopoulos; Dimitrios Bafaloukos; Dimitrios Pectasides; George Fountzilas; John M Kirkwood
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
The New England journal of medicine 2006;354(7):709-18.
2006: Michail Ignatiadis; Aristidis Polyzos; George P Stathopoulos; Evangelos Tselepatiotis; Charalambos Christophylakis; Kostas Kalbakis; Lambros Vamvakas; Athanasios Kotsakis; Anna Potamianou; Vassilis Georgoulias
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.
Oncology 2006;71(3-4):159-63.
2006: Athanasios Kotsakis; Ch Kouroussis; Nikolaos Androulakis; Sofia Agelaki; Kostas Kalbakis; Lambros Vamvakas; Nikolaos Vardakis; Antonia Kalykaki; Aristidis Polyzos; Vassilis Georgoulias; Dimitris Mavroudis
A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors.
Oncology 2006;71(3-4):190-6.
2006: Nikolaos Androulakis; Gerasimos Aravantinos; Konstantinos Syrigos; Aristidis Polyzos; Nikolaos Ziras; Evangelos Tselepatiotis; George Samonis; Nikolaos Kentepozidis; Stylianos Giassas; Lambros Vamvakas; Vassilis Georgoulias
Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study.
Oncology 2006;70(4):280-4.
2005: Vassilis Georgoulias; Athina Agelidou; Konstantinos Syrigos; Ageliki Rapti; Maria Agelidou; J Nikolakopoulos; Aristidis Polyzos; Athanasios Athanasiadis; Evangelos Tselepatiotis; Nikolaos Androulakis; Kostas Kalbakis; George Samonis; Dimitris Mavroudis
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
British journal of cancer 2005;93(7):763-9.
2005: Aristidis Polyzos; Christos Kosmas; Helen Toufexi; Nikolaos Malamos; Antonios Lagadas; Christos Kosmidis; Panagiotis Ginopoulos; Nikolaos Ziras; Kostas Kandilis; Vassilis Georgoulias
Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.
Anticancer research 2005;25(5):3559-64.
2005: Aristidis Polyzos; Nicolas Tsavaris; Irene Vafiadis; K Polyzos; John Griniatsos; Evangelos Felekouras; Nikolaos Nikiteas; S Halikias; George C Nikou
Phase II study of gemcitabine plus 5-fluorouracil biologically modulated by folinic acid plus long-acting formulation of octreotide (LAR) in patients with advanced pancreatic cancer.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2005;10(3):357-64.
2005: Christos Kosmas; Nicolas Tsavaris; Nikolaos Malamos; George Tsakonas; Argyris Gassiamis; Helias Skopelitis; Georgia Soukouli; Aristidis Polyzos; Nicolas Mylonakis; Athanasios Karabelis
Dose escalation of docetaxel and ifosfamide in patients with advanced breast cancer failing prior anthracyclines: mature results of a phase I-II study.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2005;10(3):337-46.
2005: George C Nikou; Christos Toubanakis; Panagiota Nikolaou; Eleanna Giannatou; Michael C Safioleas; Elias Mallas; Aristidis Polyzos
VIPomas: an update in diagnosis and management in a series of 11 patients.
Hepato-gastroenterology 2005;52(64):1259-65.
2005: Dimitrios Bafaloukos; Dimosthenis A Tsoutsos; Haralambos Kalofonos; S Chalkidou; Petros Panagiotou; E Linardou; Evangelos Briassoulis; Eleni Efstathiou; Aristidis Polyzos; George Fountzilas; Christos Christodoulou; Charalambos Kouroussis; Thomais Iconomou; Helen Gogas
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(6):950-7.
2005: Vassilis Georgoulias; Alexandros Ardavanis; Xanthi Tsiafaki; Athina Agelidou; Penelope Mixalopoulou; Ourania Anagnostopoulou; Panagiotis Ziotopoulos; Michael Toubis; Konstantinos Syrigos; Nikolaos Samaras; Aristidis Polyzos; Anna Christou; Stylianos Kakolyris; Charalambos Kouroussis; Nikolaos Androulakis; George Samonis; Dora Chatzidaki
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2937-45.
2005: Aristidis Polyzos; Konstantinos Syrigos; John Stergiou; Christos Panopoulos; Anna Potamianou; Lambros Vamvakas; Vassilis Georgoulias
Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma.
Cancer chemotherapy and pharmacology 2005;55(5):466-70.
2005: Anna Potamianou; Nikolaos Androulakis; Pavlos Papakotoulas; Helen Toufexi; Christos Latoufis; Charalambos Kouroussis; Charalambos Christofilakis; Nikos Xenidis; Vassilis Georgoulias; Aristidis Polyzos
Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
Oncology 2005;69(4):348-53.
2005: Christos Kosmas; Nicolas Tsavaris; Angelos Koutras; Thomas Makatsoris; Nicolas Mylonakis; George Tzelepis; Antonios Dimitrakopoulos; Konstantinos Spyropoulos; Aristidis Polyzos; Athanasios Karabelis; Haralabos P Kalofonos
A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
Oncology 2005;69(4):333-41.
2005: Nikolaos Androulakis; Konstantinos Syrigos; Aristidis Polyzos; Gerasimos Aravantinos; George P Stathopoulos; Nikolaos Ziras; Konstantinos Mallas; Lambros Vamvakas; Vassilis Georgoulis
Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study.
Cancer investigation 2005;23(1):9-12.
2004: Vassilis Georgoulias; Charalambos Kouroussis; Athina Agelidou; Ioannis Boukovinas; P Palamidas; E Stavrinidis; Aristidis Polyzos; Konstantinos Syrigos; Marinos Veslemes; Michael Toubis; Alexandros Ardavanis; Evangelos Tselepatiotis; I Vlachonikolis
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
British journal of cancer 2004;91(3):482-8.
2004: John Souglakos; Konstantinos Syrigos; Anna Potamianou; Aristidis Polyzos; Ioannis Boukovinas; Nikolaos Androulakis; Ch Kouroussis; Nikolaos Vardakis; Ch Christophilakis; Athanasios Kotsakis; Vassilis Georgoulias
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(8):1204-9.
2004: Vassilis Georgoulias; Alexandros Ardavanis; Athina Agelidou; Maria Agelidou; Vassilis Chandrinos; Emilia Tsaroucha; Michael Toumbis; Charalambos Kouroussis; Konstantinos Syrigos; Aristidis Polyzos; Nikolaos Samaras; Pavlos Papakotoulas; Charalambos Christofilakis; Nikolaos Ziras; Athanasios Alegakis
Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(13):2602-9.
2004: Helen Gogas; Dimitrios Bafaloukos; John Ioannovich; Dimosthenis Skarlos; Aristidis Polyzos; George Fountzilas; Haralabos P Kalofonos; Gerasimos Aravantinos; Dimosthenis A Tsoutsos; Petros Panagiotou; Konstantina Frangia; Theodora Petrakopoulou; Dimitrios Pectasides
Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
Anticancer research 2004;24(3b):1947-52.
2004: Nicolas Tsavaris; Christos Kosmas; Panagiotis Gouveris; Kostas Gennatas; Aristidis Polyzos; Despina Mouratidou; Heraklis Tsipras; Heraklis Margaris; George Papastratis; Evanthia Tzima; Nikitas Papadoniou; Gabriel Karatzas; Efstathios Papalambros
Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.
Investigational new drugs 2004;22(2):193-8.
2004: Sofia Agelaki; Marinos Veslemes; Konstantinos Syrigos; Filippos Palamidas; Aristidis Polyzos; Pavlos Papakotoulas; Nikolaos Kentepozidis; Georgia Milaki; Nikolaos Tzanakis; Charalambos Kouroussis; Lambros Vamvakas; Vassilis Georgoulias
A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2004;43(3):329-33.
2004: George P Stathopoulos; Konstantinos Syrigos; Aristidis Polyzos; G Fountzilas; Sotiris K Rigatos; Nikolaos Ziras; A Potamiannou; I Tsiakopoulos; Nikolaos Androulakis; Gerasimos Aravantinos; Athanasios Athanasiadis; Pavlos Papakotoulas; Vassilis Georgoulias
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(2):224-9.
2004: Aristidis Polyzos; Nicolas Tsavaris; Christos Kosmas; Helen Gogas; George Koutinos; Nikolaos Nikiteas; Evangelos Felekouras; Gregory Kouraklis; Othon Papadopoulos; Antonios Papachristodoulou; Dimitrios Stamatiadis; Michael C Safioleas; George C Nikou
Weekly Gemcitabine plus Fluorouracil-Folinic Acid Given Weekly for Two Days in Patients with Advanced Pancreatic Cancer : A Phase II Study.
Clinical drug investigation 2004;24(11):661-70.
2004: Helen Gogas; Dimitrios Bafaloukos; Gerasimos Aravantinos; George Fountzilas; Dimosthenis A Tsoutsos; Petros Panagiotou; Konstantina Frangia; Haralabos P Kalofonos; E Briasoulis; Ourania Castana; Aristidis Polyzos; Dimitrios Pectasides; John Ioannovich
Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Cancer investigation 2004;22(6):832-9.
2004: Dimitris Mavroudis; Nikolaos Malamos; Aristidis Polyzos; Ch Kouroussis; Ch Christophilakis; I Varthalitis; Nikolaos Androulakis; Kostas Kalbakis; Georgia Milaki; Vassilis Georgoulias
Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
Oncology 2004;67(3-4):250-6.
2003: Aristidis Polyzos; Nicolas Tsavaris; Christos Kosmas; Helen Gogas; Helen Toufexi; Christos Kosmidis; Christos Markopoulos; Aris Giannopoulos; Othon Papadopoulos; Dimitrios Stamatiadis; Gregory Kouraklis
Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study.
Journal of chemotherapy (Florence, Italy) 2003;15(6):607-12.
2003: Nicolas Tsavaris; Nikolaos Ziras; Christos Kosmas; THEODORE GIANNAKAKIS; Panagiotis Gouveris; Maria Vadiaka; Antonios Dimitrakopoulos; Dimitra Karadima; Sofia Rokana; Efstathios Papalambros; George Papastratis; Heraklis Margaris; Heraklis Tsipras; Aristidis Polyzos
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Cancer chemotherapy and pharmacology 2003;52(6):514-9.
2003: Aristidis Polyzos; Gregory Kouraklis; Aris Giannopoulos; J Bramis; Johanna K Delladetsima; P P Sfikakis
Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients.
Journal of chemotherapy (Florence, Italy) 2003;15(5):503-6.
2003: Aristidis Polyzos; Nicolas Tsavaris; Christos Kosmas; Helen Gogas; Maria Vadiaka; Christos Markopoulos; Aris Giannopoulos; Nikolaos Kalahanis; Dimitrios Stamatiadis; Gregory Kouraklis; Gabriel Karatzas; Christos D Liapis; Konstantinos Syrigos
Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
Anticancer research 2003;23(3C):2917-23.
2003: Christos Kosmas; Nicolas Tsavaris; Nikolaos Malamos; Niki Stavroyianni; Achilleas Gregoriou; Sofia Rokana; Aristidis Polyzos
Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer.
British journal of cancer 2003;88(8):1168-74.
2002: Helen Gogas; G Kefala; Dimitrios Bafaloukos; Konstantina Frangia; Aristidis Polyzos; Dimitrios Pectasides; Dimosthenis A Tsoutsos; Petros Panagiotou; John Ioannovich; Dimitris Loukopoulos
Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon.
British journal of cancer 2002;87(2):181-6.
2002: Nicolas Tsavaris; Aristidis Polyzos; Kostas Gennatas; Christos Kosmas; Maria Vadiaka; Antonios Dimitrakopoulos; Anastasios Macheras; George Papastratis; Heraklis Tsipras; Heraklis Margaris; Efstathios Papalambros; Aris Giannopoulos; Ch Koufos
Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination.
Chemotherapy 2002;48(2):94-9.
2002: George P Stathopoulos; Sotiris K Rigatos; G Fountzilas; Aristidis Polyzos; John G Stathopoulos
Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study.
Oncology reports 2002;9(1):89-92.
2001: Christos Kosmas; Nicolas Tsavaris; Maria Vadiaka; Niki Stavroyianni; Angelos Koutras; Nikolaos Malamos; Adimchi Onyenadum; Sofia Rokana; Aristidis Polyzos; Haralabos P Kalofonos
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Cancer 2001;92(11):2902-10.
2001: Nicolas Tsavaris; Christos Kosmas; Aristidis Polyzos; K Genatas; Maria Vadiaka; P Paliaros; Antonios Dimitrakopoulos; Sofia Rokana; Gabriel Karatzas; P Vachiotis; K Fotiadis
Leucovorin + 5-fluorouracil plus dipyridamole in leucovorin + 5-fluorouracil-pretreated patients with advanced colorectal cancer: a pilot study of three different dipyridamole regimens.
Tumori 2001;87(5):303-7.
2001: Aristidis Polyzos; Nicolas Tsavaris; Christos Kosmas; T Arnaouti; Nikolaos Kalahanis; Christos Tsigris; Aris Giannopoulos; Gabriel Karatzas; L Giannikos; P P Sfikakis
Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.
Oncology 2001;61(2):129-33.
2000: Christos Kosmas; Nicolas Tsavaris; Aristidis Polyzos; Haralabos P Kalofonos; Evangelos Sepsas; Nikolaos Malamos; Maria Vadiaka; Theodosios Dosios; Minas J Antonopoulos
A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
Cancer 2000;89(4):774-82.
2000: Christos Kosmas; Nicolas Tsavaris; Aristidis Polyzos; Nikolaos Malamos; M Katsikas; Minas J Antonopoulos
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
British journal of cancer 2000;82(2):300-7.
1999: Aristidis Polyzos; Nicolas Tsavaris; Christos Kosmas; G Petrikos; L Giannikos; Nikolaos Kalahanis; Othon Papadopoulos; Kostantinos Christodoulou; Kostas Giannakopoulos; Marinos Veslemes; Nikolaos Katsilambros
Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
Journal of chemotherapy (Florence, Italy) 1999;11(2):144-9.
1999: Aristidis Polyzos; Nicolas Tsavaris; Christos Kosmas; L Giannikos; M Katsikas; Nikolaos Kalahanis; Gabriel Karatzas; Kostantinos Christodoulou; Kostas Giannakopoulos; Dimitrios Stamatiadis; Nikolaos Katsilambros
A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer.
Oncology 1999;56(4):291-6.
1998: Marinos Veslemes; Aristidis Polyzos; Panagiota Latsi; IOANNIS DIMITROULIS; Dimitrios Stamatiadis; Costas E Dardoufas; A Rasidakis; Nikolaos Katsilambros; JB Jordanoglou
Optimal duration of chemotherapy in small cell lung cancer: a randomized study of 4 versus 6 cycles of cisplatin-etoposide.
Journal of chemotherapy (Florence, Italy) 1998;10(2):136-40.
1997: Aristidis Polyzos; Nicolas Tsavaris; Marinos Veslemes; Konstantinos Dardoufas; Theodosios Dosios; Christos Kosmas
Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine.
Journal of chemotherapy (Florence, Italy) 1997;9(2):102-5.
1997: Nicolas Tsavaris; Aristidis Polyzos; Christos Kosmas; L Giannikos; John Gogas
A feasibility study of 1-h paclitaxel infusion in patients with solid tumors.
Cancer chemotherapy and pharmacology 1997;40(4):353-7.
1996: Aristidis Polyzos; G Nikou; Aris Giannopoulos; A Toskas; Nikolaos Kalahanis; J Papargyriou; P Michail; Antonios Papachristodoulou
Chemotherapy of biliary tract cancer with mitomycin-C and 5-fluorouracil biologically modulated by folinic acid. A phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(6):644-5.
1996: Aristidis Polyzos; Nicolas Tsavaris; Aris Giannopoulos; Christos Bacoyiannis; V Papadimas; Nikolaos Kalahanis; Gabriel Karatzas; Christos Kosmas; N Sakelaropoulos; Athanasios Archimandritis; Antonios Papachristodoulou; Paris A Kosmidis
Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
Cancer chemotherapy and pharmacology 1996;38(3):292-7.
1995: Marinos Veslemes; Aristidis Polyzos; P Latsi; IOANNIS DIMITROULIS; K Dimakou; JB Jordanoglou
Outcome of patients with brain metastases after combined modality therapy in small cell lung cancer (SCLC): a retrospective study.
Journal of chemotherapy (Florence, Italy) 1995;7(5):460-2.
1995: Aristidis Polyzos; C Gennatas; Marinos Veslemes; E Daskalopoulou; Dimitrios Stamatiadis; Nikolaos Katsilambros
The smoking-cessation promotion practices of physician smokers in Greece.
Journal of cancer education : the official journal of the American Association for Cancer Education 1995;10(2):78-81.
1989: E Xefteri; Aristidis Polyzos; L Tzianoumis; M Tiniakoy; H Goumakou; E Pagalou; K Kotsis; Petros P Sfikakis
VAD for remission induction as a first line and in relapsed adult acute lymphoblastic leukemia (ALL).
Journal of chemotherapy (Florence, Italy) 1989;1(4 Suppl):1271-2.
1989: Aristidis Polyzos; L Giannikos; A Agrafiotis; M Kazaz; C Zonas; Petros P Sfikakis
Intraperitoneal chemotherapy in ovarian carcinoma with the combination of carboplatin and 5-fluorouracil.
Journal of chemotherapy (Florence, Italy) 1989;1(4 Suppl):1220-1.
1989: Aristidis Polyzos; E Koulentianos; L Tzianoumis; Petros P Sfikakis
Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
Journal of chemotherapy (Florence, Italy) 1989;1(4 Suppl):1185-6.
1980: Nikolaos Katsilambros; Aristidis Polyzos; H Makriyannis; P Stavrou; P Philippides; N Moiras; G K Daikos
[Effect of leucine on blood insulin levels and intravenous glucose tolerance].
Journées annuelles de diabétologie de l'Hôtel-Dieu 1980;():59-64.